<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName nlm2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Immunology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1664-3224</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9813736</article-id>
    <article-id pub-id-type="doi">10.3389/fimmu.2022.1053617</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Immunology</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>AbAgIntPre: A deep learning method for predicting antibody-antigen interactions based on sequence information</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Huang</surname>
          <given-names>Yan</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1127004"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Zhang</surname>
          <given-names>Ziding</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn001" ref-type="author-notes">
          <sup>*</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/182491"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Zhou</surname>
          <given-names>Yuan</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="fn001" ref-type="author-notes">
          <sup>*</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/432210"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>State Key Laboratory of Agrobiotechnology, College of Biological Sciences, China Agricultural University</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Department of Biomedical Informatics, Key Laboratory of Molecular Cardiovascular Sciences of the Ministry of Education, School of Basic Medical Sciences, Peking University</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Gurudeeban Selvaraj, Concordia University, Canada</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Feng Zhu, Zhejiang University, China; Satyavani Kaliamurthi, Concordia University, Canada</p>
      </fn>
      <corresp id="fn001">*Correspondence: Ziding Zhang, <email xlink:href="mailto:zidingzhang@cau.edu.cn">zidingzhang@cau.edu.cn</email>; Yuan Zhou, <email xlink:href="mailto:zhouyuanbioinfo@hsc.pku.edu.cn">zhouyuanbioinfo@hsc.pku.edu.cn</email>
</corresp>
      <fn fn-type="other" id="fn002">
        <p>This article was submitted to Systems Immunology, a section of the journal Frontiers in Immunology</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>22</day>
      <month>12</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>13</volume>
    <elocation-id>1053617</elocation-id>
    <history>
      <date date-type="received">
        <day>26</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>14</day>
        <month>12</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2022 Huang, Zhang and Zhou</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Huang, Zhang and Zhou</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <sec>
        <title>Introduction</title>
        <p>Antibody-mediated immunity is an essential part of the immune system in vertebrates. The ability to specifically bind to antigens allows antibodies to be widely used in the therapy of cancers and other critical diseases. A key step in antibody therapeutics is the experimental identification of antibody-antigen interactions, which is generally time-consuming, costly, and laborious. Although some computational methods have been proposed to screen potential antibodies, the dependence on 3D structures still limits the application of these methods.</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p>Here, we developed a deep learning-assisted prediction method (i.e., AbAgIntPre) for fast identification of antibody-antigen interactions that only relies on amino acid sequences. A Siamese-like convolutional neural network architecture was established with the amino acid composition encoding scheme for both antigens and antibodies.</p>
      </sec>
      <sec>
        <title>Results and Discussion</title>
        <p>The generic model of AbAgIntPre achieved satisfactory performance with the Area Under Curve (AUC) of 0.82 on a high-quality generic independent test dataset. Besides, this approach also showed competitive performance on the more specific SARS-CoV dataset. We expect that AbAgIntPre can serve as an important complement to traditional experimental methods for antibody screening and effectively reduce the workload of antibody design. The web server of AbAgIntPre is freely available at <uri xlink:href="http://www.zzdlab.com/AbAgIntPre">http://www.zzdlab.com/AbAgIntPre</uri>.</p>
      </sec>
    </abstract>
    <kwd-group>
      <kwd>antibody-antigen interaction</kwd>
      <kwd>deep learning</kwd>
      <kwd>sequence feature</kwd>
      <kwd>SARS-CoV</kwd>
      <kwd>Siamese-like convolutional neural network</kwd>
      <kwd>webserver</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source id="cn001">
          <institution-wrap>
            <institution>National Key Research and Development Program of China
</institution>
            <institution-id institution-id-type="doi">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source id="cn002">
          <institution-wrap>
            <institution>National Natural Science Foundation of China
</institution>
            <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <fig-count count="5"/>
      <table-count count="0"/>
      <equation-count count="4"/>
      <ref-count count="50"/>
      <page-count count="10"/>
      <word-count count="4474"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>Introduction</title>
    <p>Antibody-mediated immunity is an essential part of the immune system in vertebrates. Antibodies are a special class of proteins with Y shape. One key responsibility of these proteins is the specific recognition and neutralization of foreign agents. The root of the specificity of antibodies to a particular antigen can be traced to the diversity of each tip of antibodies’ Y-shaped structures (<xref rid="B1" ref-type="bibr">1</xref>). This binding specificity of antibodies has been widely used in the biotechnology and biopharmaceutical industry, where monoclonal antibodies (MAbs) have become the most promising therapeutic method in the market because of their high specificities and long half-lives (<xref rid="B2" ref-type="bibr">2</xref>–<xref rid="B4" ref-type="bibr">4</xref>). With the rapid advances in bioengineering, more MAb derivatives with greater affinity and specificity are available such as antibody-drug conjugates (ADCs) and fusion proteins (<xref rid="B5" ref-type="bibr">5</xref>).</p>
    <p>One latest application of MAbs is for the treatment of coronavirus disease 2019 (COVID-19). The COVID-19 pandemic has placed a heavy burden on society. Currently, there are a variety of vaccine strategies, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, to provide protection against COVID-19 (<xref rid="B6" ref-type="bibr">6</xref>). All the vaccine strategies aim at enabling the immune system to produce antibodies that bind to the antigens from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral pathogen causing COVID-19. But some patients may not be suitable for vaccination due to a severe allergic reaction or may fail to mount a protective immune response through vaccines (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Therefore, a shortcut turns out to be directly treating the COVID-19 patients with the specific MAb against SARS-CoV-2. Indeed, very recently, anti-SARS-CoV-2 MAbs, including Bebtelovimab and Tixagevimab plus cilgavima, have been approved by FDA for treatment or pre-exposure prophylaxis against COVID-19, suggesting MAbs can become an effective complement to vaccines (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). On the other hand, some other MAbs fail to obtain FDA authorization because of their reduced efficiency against the current Omicron variant of COVID-19 (<xref rid="B11" ref-type="bibr">11</xref>), which again stressed the importance of the recognition of antibody-antigen specificity.</p>
    <p>Given the importance of identifying the antibody-antigen recognition specificity, radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA) methods have been widely applied to identify the affinity and specificity of antibody-antigen interactions (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Due to the coating contamination of RIA and the false positives caused by non-specific and staggered reactions in ELISA, surface plasmon resonance (SPR), fluorescence activated cell sorting (FACS), bio-layer interferometry (BLI), cryogenic electron microscopy (cryo-EM) and other technologies are often used to detect the specificity of antibodies more accurately. However, some of these experimental methods are labor intensive, time-consuming, and costly. In addition, these experimental methods are unsuitable for large-scale high-throughput antibody screening.</p>
    <p>On the other hand, the increasing availability of experimental data of antibody-antigen interaction provides valuable guidance for the development of computational approaches. The International ImmunoGeneTics (IMGT) information system is the most well-known immunity-related database that integrates sequence, genome, and structure immunogenetic data (<xref rid="B14" ref-type="bibr">14</xref>). Other sequence databases such as Database of ImmunoGlobulins with Integrated Tools (DIGIT) (<xref rid="B15" ref-type="bibr">15</xref>), abYsis (<xref rid="B16" ref-type="bibr">16</xref>), iReceptor (<xref rid="B17" ref-type="bibr">17</xref>), and Observed Antibody Space (OAS) (<xref rid="B18" ref-type="bibr">18</xref>) also source a large amount of sequencing data indicating antibody-antigen interaction. The Immune Epitope Database (IEDB) is established mainly for epitopes (<xref rid="B19" ref-type="bibr">19</xref>). The experimental data on antibody and T cell epitopes in the context of disease, allergy, autoimmunity and transplantation provides a reference for antibody design and immunotherapy development. Among these antibody-related databases, the structural antibody database (SAbDab) collects all the available antigen-antibody complexes in the Protein Data Bank (PDB) (<xref rid="B20" ref-type="bibr">20</xref>). Various types of antigens with their binding antibodies have provided insights for understanding the generic mechanisms of antigen-antibody binding. In contrast to SAbDab, the Coronavirus antibody database (CoV-AbDab) collected antibodies that bind to at least one beta coronavirus (<xref rid="B21" ref-type="bibr">21</xref>). Up to now (Version of July 2022), CoV-AbDab has included approximately 10,000 entries, which are valuable for the fundamental research of SARS-CoV-2 and the development of the corresponding vaccines and drugs.</p>
    <p>Thanks to the increasingly available experimental data, several computational approaches for computational antibody design have been developed. Molecular docking is a classical method for predicting antibody-antigen binding mode and relative positions. However, molecular docking is often computationally expensive, especially when dealing with flexible molecules such as antibodies (<xref rid="B22" ref-type="bibr">22</xref>). The emergence of epitope or paratope prediction tools based on structural or sequence features, such as PECAN (<xref rid="B23" ref-type="bibr">23</xref>), BepiPred2.0 (<xref rid="B24" ref-type="bibr">24</xref>), and Epipred (<xref rid="B25" ref-type="bibr">25</xref>), greatly reduces the search space of docking. Many software or tools can directly predict antibody-antigen interactions. Lim et al. predicted the binding of PD-1 and CTLA-4 antibodies by training a convolutional neural network (CNN) with complementarity-determining region (CDR) sequence features (<xref rid="B26" ref-type="bibr">26</xref>). By using the multi-head attention network with position-embedding of CDRs, Wang et al. developed a model which can accurately distinguish the antibodies binding to the SARS-CoV-2 S protein and influenza HA (<xref rid="B27" ref-type="bibr">27</xref>). These computational methods provide alternative choices for early screening and effectively supplement experimental methods.</p>
    <p>Still, the aforementioned computational methods have issues to be improved: (i) Most of them require the structural information of antigens or antibodies which are hard to obtain; (ii) These methods are often implemented for one specific antigen, and therefore are not widely applicable; (iii) The published algorithms or tools did not have a user-friendly interface for non-specialists to use. To this end, we proposed AbAgIntPre, an online tool to predict the interactions between antibodies and antigens based only on the sequence features. AbAgIntPre combines the composition of k-spaced amino acid pairs (CKSAAP) encoding and CNN deep learning framework for an efficient prediction of antibody-antigen interactions. AbAgIntPre enables general antigen-antibody interaction prediction by capturing various types of antigens. We also established a specific interaction prediction model for coronavirus, including severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and SARS-CoV-2. For the convenience of the community, we have implemented AbAgIntPre as a web server with a friendly interface. Users can freely select the generic model and SARS-CoV-specific model to meet their needs.</p>
  </sec>
  <sec id="s2">
    <title>Methods</title>
    <sec id="s2_1">
      <title>Datasets</title>
      <p>Many structures of antibodies and corresponding antigens are collected in the SAbDab database (<xref rid="B20" ref-type="bibr">20</xref>). We selected antibodies with heavy and light chain information and removed those complexes with antigenic sequences less than 50 amino acids (<xref rid="B28" ref-type="bibr">28</xref>). After applying this restriction, 1489 antibody-antigen complexes were retained. Considering the high specificity of the antibodies, we removed the sequence redundancy according to antibodies by applying CD-HIT (<xref rid="B29" ref-type="bibr">29</xref>) with a high sequence identity threshold of 0.98 and obtained 918 complexes. Because of the high specificity of the antibodies, we further divided the 918 complexes into 408 subgroups based on antigen sequences with a sequence identity threshold of 0.90. By the above procedures, we assumed that similar antibodies can bind similar antigens within the same subgroup, while the antigens and antibodies from different subgroups cannot bind to each other effectively (<xref rid="f1" ref-type="fig"><bold>Figure 1A</bold></xref>). As a result, we generated 3892 antibody-antigen pairs as the positive samples. Antigens and antibodies from different subgroups were randomly paired to form the negative samples, and the ratio of positive to negative samples was controlled to be 1: 1. Considering that the sequences of antibodies binding to different types of antigens are quite different, models may not perform satisfactorily in predicting the antigens which are quite different from those used in training. To this end, we used ClustalW (<xref rid="B30" ref-type="bibr">30</xref>) to establish the phylogenetic tree for antigens in the above 408 subgroups and divided these subgroups into seven clusters (<xref rid="f1" ref-type="fig"><bold>Figure 1B</bold></xref>). The training set and independent test set were generated from each cluster according to a ratio of 4:1 to ensure that no bias was introduced by the differences in antigen types.</p>
      <fig position="float" id="f1">
        <label>Figure 1</label>
        <caption>
          <p>Overview of AbAgIntPre. <bold>(A)</bold> Flowchart of the generic prediction model of AbAgIntPre. <bold>(B)</bold> Clustering tree of 918 antigens in 408 subgroups. <bold>(C)</bold> The Siamese-like CNN framework of AbAgIntPre.</p>
        </caption>
        <graphic xlink:href="fimmu-13-1053617-g001" position="float"/>
      </fig>
      <p>We also collected antibodies binding to SARS-CoV and trained a SARS-CoV-specific predictor. SARS-CoV antibody data were collected from CoV-AbDab (<xref rid="B21" ref-type="bibr">21</xref>) and screened out the antibodies related to SARS-CoV-1 and SARS-CoV-2. Antibodies that could only bind to one SARS-CoV were taken as the positive samples, and those that could not bind to SARS-CoV were taken as the negative samples. A total of 9309 positive samples and 1710 negative samples were obtained, including 1965 positive samples of SARS-CoV-1, 7344 positive samples of SARS-CoV-2, 996 negative samples of SARS-CoV-2 and 714 negative samples of SARS-CoV-2.</p>
    </sec>
    <sec id="s2_2">
      <title>Sequence encoding</title>
      <p>The previous literature has shown that the sequence compositions can effectively reflect the properties of antibodies such as specificity, stability, viscosity and immunogenicity. For example, Hebditch et al. predicted the solubility of antibodies by using a linear model with amino acid compositions and several other sequence features (<xref rid="B31" ref-type="bibr">31</xref>). Liaw et al. developed an algorithm for predicting amyloidogenesis of light chains of antibodies based on a random forest (RF) classifier with dipeptide composition (DPC) (<xref rid="B32" ref-type="bibr">32</xref>). Several analyses have demonstrated that there is also a preference of residues or motifs in epitopes of specific antibody (<xref rid="B33" ref-type="bibr">33</xref>–<xref rid="B35" ref-type="bibr">35</xref>). Kadam et al. developed a classifier for predicting antibody class(es) for epitopes with sequence composition features (<xref rid="B36" ref-type="bibr">36</xref>). El-Manzalawy et al. predicted flexible length linear B-cell epitopes by using support vector machine (SVM) with amino acid pairs encoding strategy (<xref rid="B37" ref-type="bibr">37</xref>).</p>
      <p>In this study, we used CKSAAP as the preferred sequence composition-based encoding strategy. CKSAAP summarizes the frequency of k-spaced amino acid pairs normalized by all possible 400 kinds of pair combinations (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>), which reflected the amino acid composition of the antibodies and the residue preference of epitopes in antigens. To capture the characteristics of protein sequence more comprehensively, we calculated the results of each protein when <italic>k</italic> = 0,1,2,3. Therefore, each protein is represented as a 1600-dimensional vector.</p>
      <p>We also compared the performance of CKSAAP encoding with those of the alternative encodings, including:</p>
      <sec id="s2_2_1">
        <title>One-hot encoding</title>
        <p>One-hot encoding is a typical sequence coding strategy in machine learning (ML). In one-hot encoding, we used a 20-bit vector of ‘0’ or ‘1’ to represent 20 kinds of amino acids, ‘1’ at each position denotes a specific amino acid, and ‘0’ for the rest of bits (<xref rid="B40" ref-type="bibr">40</xref>).</p>
      </sec>
      <sec id="s2_2_2">
        <title>Position-specific scoring matrix encoding</title>
        <p>In PSSM profiles, each residue in query protein is encoded as a 20-dimensional vector, in which each element reflects the conservation of 20 kinds of amino acids at corresponding position among a set of homologous sequences (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). We generated the PSSM profiles of all the antigens and antibodies by applying PSI-BLAST (<xref rid="B43" ref-type="bibr">43</xref>) search against the NR90 database with three iterations. The e-value cutoff for including sequences in the profiles was set to 0.0001, and other parameters remained the default.</p>
      </sec>
      <sec id="s2_2_3">
        <title>DPC encoding</title>
        <p>DPC encoding uses a 400-dimensional vector to capture the character of the protein sequence (<xref rid="B44" ref-type="bibr">44</xref>). Each dimension corresponds to the frequency of a specific dipeptide combination in the query protein sequence.</p>
      </sec>
      <sec id="s2_2_4">
        <title>Word2Vec embedding</title>
        <p>In natural language processing, word2vec has been widely used to obtain the distributed representation of words (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>). The k-mers in protein sequences can be regarded as words in a document. Therefore, we trained a CBOW-based word2vec model with protein sequences in NR90 by using the <italic>genism</italic> of the python package. Each sequence was divided into several k-mers, and each k-mer was represented by a 64-dimensional embedding vector. In this study, we set k to 3 and set the window size to 4 to capture the context information.</p>
      </sec>
    </sec>
    <sec id="s2_7">
      <title>Deep learning framework</title>
      <p>In this study, we used a Siamese-like CNN as the deep learning classifier to infer whether the query antigen and antibody can interact (<xref rid="f1" ref-type="fig"><bold>Figure 1C</bold></xref>). Specifically, our model mainly included three parts: input module, convolution module, and prediction module. In the input module, antigens or antibodies were coded by CKSAAP encoding scheme, and four channels correspond to four k-spaced values in CKSAAP. The convolution module further processed the encoded feature vectors. AbAgIntPre included two convolution modules, each of which consists of a batch normalization layer, convolution layer, rectified linear unit, and pooling. Two fully connected layers were used to map the learned distributed features to the sample label space and yield the probability of interaction between the given antigen and antibody.</p>
      <p>We also compared the performance of our deep learning framework with those of several traditional ML models, including RF, SVM, Adaboost (ADA), logistic regression (LR), and multilayer perceptron (MLP). All the traditional ML models were implemented through the <italic>sklearn</italic> (<uri xlink:href="https://scikit-learn.org/">https://scikit-learn.org/</uri>) of the python package.</p>
    </sec>
    <sec id="s2_8">
      <title>Performance evaluation</title>
      <p>In this study, we used receiver operating characteristic (ROC) and precision-recall (PR) curves to measure the performance of the predictors. ROC and PR curves reflect the overall relationship between sensitivity and specificity and the overall relationship between precision and recall when different thresholds are applied. The definitions of sensitivity (i.e., recall), specificity, and precision are as follows:</p>
      <disp-formula>
        <mml:math id="M1" display="block" overflow="scroll">
          <mml:mrow>
            <mml:mi>S</mml:mi>
            <mml:mi>e</mml:mi>
            <mml:mi>n</mml:mi>
            <mml:mi>s</mml:mi>
            <mml:mi>i</mml:mi>
            <mml:mi>t</mml:mi>
            <mml:mi>i</mml:mi>
            <mml:mi>v</mml:mi>
            <mml:mi>i</mml:mi>
            <mml:mi>t</mml:mi>
            <mml:mi>y</mml:mi>
            <mml:mo>=</mml:mo>
            <mml:mi>R</mml:mi>
            <mml:mi>e</mml:mi>
            <mml:mi>c</mml:mi>
            <mml:mi>a</mml:mi>
            <mml:mi>l</mml:mi>
            <mml:mi>l</mml:mi>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mrow>
                <mml:mi>T</mml:mi>
                <mml:mi>P</mml:mi>
              </mml:mrow>
              <mml:mrow>
                <mml:mi>T</mml:mi>
                <mml:mi>P</mml:mi>
                <mml:mo>+</mml:mo>
                <mml:mi>F</mml:mi>
                <mml:mi>N</mml:mi>
              </mml:mrow>
            </mml:mfrac>
          </mml:mrow>
        </mml:math>
      </disp-formula>
      <disp-formula>
        <mml:math id="M2" display="block" overflow="scroll">
          <mml:mrow>
            <mml:mi>S</mml:mi>
            <mml:mi>p</mml:mi>
            <mml:mi>e</mml:mi>
            <mml:mi>c</mml:mi>
            <mml:mi>i</mml:mi>
            <mml:mi>f</mml:mi>
            <mml:mi>i</mml:mi>
            <mml:mi>c</mml:mi>
            <mml:mi>i</mml:mi>
            <mml:mi>t</mml:mi>
            <mml:mi>y</mml:mi>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mrow>
                <mml:mi>T</mml:mi>
                <mml:mi>N</mml:mi>
              </mml:mrow>
              <mml:mrow>
                <mml:mi>T</mml:mi>
                <mml:mi>N</mml:mi>
                <mml:mo>+</mml:mo>
                <mml:mi>F</mml:mi>
                <mml:mi>P</mml:mi>
              </mml:mrow>
            </mml:mfrac>
          </mml:mrow>
        </mml:math>
      </disp-formula>
      <disp-formula>
        <mml:math id="M3" display="block" overflow="scroll">
          <mml:mrow>
            <mml:mi>P</mml:mi>
            <mml:mi>r</mml:mi>
            <mml:mi>e</mml:mi>
            <mml:mi>c</mml:mi>
            <mml:mi>i</mml:mi>
            <mml:mi>s</mml:mi>
            <mml:mi>i</mml:mi>
            <mml:mi>o</mml:mi>
            <mml:mi>n</mml:mi>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mrow>
                <mml:mi>T</mml:mi>
                <mml:mi>P</mml:mi>
              </mml:mrow>
              <mml:mrow>
                <mml:mi>T</mml:mi>
                <mml:mi>P</mml:mi>
                <mml:mo>+</mml:mo>
                <mml:mi>F</mml:mi>
                <mml:mi>P</mml:mi>
              </mml:mrow>
            </mml:mfrac>
          </mml:mrow>
        </mml:math>
      </disp-formula>
      <p>where TP, TN, FP, and FN denote the number of true positive, true negative, false positive, and false negative samples, respectively. The larger the area under the curve (AUC), the higher the prediction performance.</p>
      <p>In addition, to test whether antigen-antibody binding could be simply determined by sequence similarity, we also compared our models with the well-established PSI-BLAST method on the independent test set. First, testing samples were aligned to training samples by PSI-BLAST (<xref rid="B43" ref-type="bibr">43</xref>). Then, we randomly combined each antigen and antibody with top 10 E-value in the PSI-BLAST results. If there was no combination appearing in the training positive set, then the query antigen-antibody pair was considered as non-interacting with zero prediction score. Otherwise, the prediction score could be calculated as follows:</p>
      <disp-formula>
        <mml:math id="M4" display="block" overflow="scroll">
          <mml:mrow>
            <mml:mi>P</mml:mi>
            <mml:mi>r</mml:mi>
            <mml:mi>e</mml:mi>
            <mml:mi>d</mml:mi>
            <mml:mi>i</mml:mi>
            <mml:mi>c</mml:mi>
            <mml:mi>t</mml:mi>
            <mml:mi>i</mml:mi>
            <mml:mi>o</mml:mi>
            <mml:mi>n</mml:mi>
            <mml:mi>S</mml:mi>
            <mml:mi>c</mml:mi>
            <mml:mi>o</mml:mi>
            <mml:mi>r</mml:mi>
            <mml:msub>
              <mml:mi>e</mml:mi>
              <mml:mrow>
                <mml:mi>P</mml:mi>
                <mml:mi>S</mml:mi>
                <mml:mi>I</mml:mi>
                <mml:mo>−</mml:mo>
                <mml:mi>B</mml:mi>
                <mml:mi>L</mml:mi>
                <mml:mi>A</mml:mi>
                <mml:mi>S</mml:mi>
                <mml:mi>T</mml:mi>
              </mml:mrow>
            </mml:msub>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mrow>
                <mml:mn>100</mml:mn>
                <mml:mo>−</mml:mo>
                <mml:mrow>
                  <mml:mo>(</mml:mo>
                  <mml:mrow>
                    <mml:mrow>
                      <mml:mo>(</mml:mo>
                      <mml:mrow>
                        <mml:mi>R</mml:mi>
                        <mml:mi>a</mml:mi>
                        <mml:mi>n</mml:mi>
                        <mml:msub>
                          <mml:mi>k</mml:mi>
                          <mml:mrow>
                            <mml:mi>A</mml:mi>
                            <mml:mi>b</mml:mi>
                          </mml:mrow>
                        </mml:msub>
                        <mml:mo>−</mml:mo>
                        <mml:mn>1</mml:mn>
                      </mml:mrow>
                      <mml:mo>)</mml:mo>
                    </mml:mrow>
                    <mml:mo>×</mml:mo>
                    <mml:mrow>
                      <mml:mo>(</mml:mo>
                      <mml:mrow>
                        <mml:mi>R</mml:mi>
                        <mml:mi>a</mml:mi>
                        <mml:mi>n</mml:mi>
                        <mml:msub>
                          <mml:mi>k</mml:mi>
                          <mml:mrow>
                            <mml:mi>A</mml:mi>
                            <mml:mi>g</mml:mi>
                          </mml:mrow>
                        </mml:msub>
                        <mml:mo>−</mml:mo>
                        <mml:mn>1</mml:mn>
                      </mml:mrow>
                      <mml:mo>)</mml:mo>
                    </mml:mrow>
                  </mml:mrow>
                  <mml:mo>)</mml:mo>
                </mml:mrow>
              </mml:mrow>
              <mml:mrow>
                <mml:mn>100</mml:mn>
              </mml:mrow>
            </mml:mfrac>
          </mml:mrow>
        </mml:math>
      </disp-formula>
      <p>where <italic>Rank<sub>Ab</sub>
</italic> and <italic>Rank<sub>Ag</sub>
</italic> denote the ranking of E-value in PSI-BLAST results. The more similar the query antigen or antibody is to known sequences, the higher the prediction score.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>Results</title>
    <sec id="s3_1">
      <title>Establishment of AbAgIntPre generic prediction model</title>
      <p>By collecting various antigens and their corresponding antibodies in SAbDab, we have established a generic prediction model of antigen-antibody interaction. First, 918 high-quality antibody-antigen complexes were collected after data cleaning and redundancy removal. Then the 918 pairs of complexes were clustered into 408 subgroups. The high-quality positive and negative antibody-antigen pairs can be assigned based on this grouping, following the principle that similar antibodies bind similar antigens (<xref rid="f1" ref-type="fig"><bold>Figure 1B</bold></xref>; see Methods for details). In each cluster, we randomly divided the training set and the independent test set according to the ratio of 4: 1. We applied five-fold cross-validation (CV) on the training set. To select the sequence encoding method suitable for our study, we used the RF model to verify the one-hot, DPC, CKSAAP, PSSM, and word2vec encoding strategies in the five-fold CV (<xref rid="f2" ref-type="fig"><bold>Figures 2A, B</bold></xref>). <xref rid="f2" ref-type="fig"><bold>Figure 2A</bold></xref> shows that under the condition of low false positive rate, the true positive rates of word2vec, PSSM and one-hot encodings are significantly lower than those of DPC and CKSAAP encodings, which suggests that the encoding strategy based on amino acid composition is more suitable for dealing with antibody-antigen interaction issues.</p>
      <fig position="float" id="f2">
        <label>Figure 2</label>
        <caption>
          <p>Performance comparison among different sequence encoding strategies in RF model and CNN model. <bold>(A)</bold> ROC curves of the five-fold cross-validation (CV) with RF model. <bold>(B)</bold> PR curves of the five-fold CV with RF model. <bold>(C)</bold> ROC curves of the five-fold CV with CNN model. <bold>(D)</bold> PR curves of the five-fold CV with CNN model.</p>
        </caption>
        <graphic xlink:href="fimmu-13-1053617-g002" position="float"/>
      </fig>
      <p>An independent test set that was not involved in the model’s training process was further introduced to validate the performance. We trained different ML models with the same training set and compared their performances on this independent test set. Considering that antibody-antigen interaction prediction belongs to the pair-input problem, among these ML models, we focused on the Siamese-like network which is commonly used in pair-input prediction problem (<xref rid="B47" ref-type="bibr">47</xref>–<xref rid="B49" ref-type="bibr">49</xref>). Our Siamese-like CNN ensured unbiased feature extraction by sharing the parameters between the two sub-networks. Although the results of CV based on RF model showed the superiority of CKSAAP encoding, we verified the applicability of CKSAAP encoding in CNN model through the same CV dataset used in RF model. As shown in <xref rid="f2" ref-type="fig"><bold>Figure 2</bold></xref>, the results with CNN (<xref rid="f2" ref-type="fig"><bold>Figures 2C, D</bold></xref>) agree well with those with RF models (<xref rid="f2" ref-type="fig"><bold>Figures 2A, B</bold></xref>). Since CKSAAP covers a broader range of compositional features than does the capture of only adjacent amino acids, we eventually adopted CKSAAP to encode the antigen and antibody sequences in the independent test and final training of the generic model. Independent test results show that the performance of our Siamese-like CNN model outperforms other traditional ML models (<xref rid="f3" ref-type="fig"><bold>Figure 3</bold></xref>). It is also worth noting that antigen-antibody interaction cannot be accurately judged simply by sequence similarity, as the true positive rate of PSI-BLAST was lower than those of some ML methods, especially than that of the CNN architecture when requiring lower false positive rate (<xref rid="f3" ref-type="fig"><bold>Figure 3</bold></xref>). Nonetheless, due to the scarceness of samples in rare antigen groups like the CLS5 covering only 13 antigens, our model was not sufficiently trained for such cases. We believe that the performance of our model could be further improved with the increasing experimental data.</p>
      <fig position="float" id="f3">
        <label>Figure 3</label>
        <caption>
          <p>Performance comparison among different prediction models on independent test set. <bold>(A)</bold> ROC curves of the independent test. <bold>(B)</bold> PR curves of the independent test.</p>
        </caption>
        <graphic xlink:href="fimmu-13-1053617-g003" position="float"/>
      </fig>
    </sec>
    <sec id="s3_2">
      <title>Establishment of AbAgIntPre SARS-CoV-specific prediction model</title>
      <p>Due to the highly contagious and sometimes lethal, the SARS-CoV pandemics present enormous challenges to medical care, economies, and social lives in 2003 and 2020-2022. Development of therapies for SARS-like coronavirus, especially pandemic SARS-CoV-2, is urgently needed. Effective characterizing and prediction for SARS-like coronavirus would assist vaccine and MAb therapy development and facilitate the elimination of the pathogens. In this study, we also established a SARS-CoV-specific prediction model to predict the probability that the antibodies bind SARS-CoV-1 and SARS-CoV-2. The SARS-CoV-specific prediction model was trained and tested based on the antibody-antigen pair annotations from CoV-AbDab. Due to the extreme disparity in the ratio of positive samples to negative samples, we used only ROC curve to evaluate the SARS-CoV-specific model since ROC curve is less affected by the unbalanced dataset. <xref rid="f4" ref-type="fig"><bold>Figure 4</bold></xref> shows that in the five-fold CV, the performance of each fold is equivalent to that of the generic model, and this result is acceptable considering the size and the unbalanced nature of the SARS-CoV dataset.</p>
      <fig position="float" id="f4">
        <label>Figure 4</label>
        <caption>
          <p>The ROC curves of the five-fold cross-validation on the SARS-CoV dataset.</p>
        </caption>
        <graphic xlink:href="fimmu-13-1053617-g004" position="float"/>
      </fig>
    </sec>
    <sec id="s3_3">
      <title>Perturbation test on SARS-CoV-2 S protein antibodies</title>
      <p>He et al. sorted SARS-CoV-specific single B cells to isolate 107 monoclonal antibodies from two recovered patients in COVID-19 (<xref rid="B50" ref-type="bibr">50</xref>). We collected these antibodies binding to SARS-CoV-2 S protein and then predicted the 107 interactions using our SARS-CoV-specific model. Considering that the CDRs, especially the CDRH3 and L3 loops play an important role in the antibody-specific recognition, we tested the validity of the prediction by randomly replacing the residues in CDRH3 and L3 loops. Specifically, for the above 107 antibodies, we applied three different perturbation tests: perturb CDRH3, perturb CDRL3 and perturb both CDRH3 and CDRL3. Taking perturb CDRH3 as an example, we randomly replaced every amino acid located in the CDRH3 loop with any of the other 19 amino acids to mimic the antibodies with perturbed functions. <xref rid="f5" ref-type="fig"><bold>Figure 5</bold></xref> shows that predicted scores of the perturbed antibodies significantly declined compared with the original antibodies. As expected, replacing CDRH3 or CDRL3 could severely reduce the prediction scores (p-value = 6.19E-09 and 1.13E-12, respectively), while the impact of the replacement of CDRH3 and CDRL3 together was the most significant (p-value = 1.67E-22).</p>
      <fig position="float" id="f5">
        <label>Figure 5</label>
        <caption>
          <p>Perturbation test on SARS-CoV-2 S protein antibodies. <bold>(A)</bold> Prediction score distribution of SARS-CoV-2 S protein with antibodies under different perturbation strategies. <bold>(B)</bold> T-test results between different perturbation groups. Value in each heatmap cell represents the -log<sub>10</sub> (p-value).</p>
        </caption>
        <graphic xlink:href="fimmu-13-1053617-g005" position="float"/>
      </fig>
    </sec>
    <sec id="s3_4">
      <title>AbAgIntPre web server</title>
      <p>To facilitate the community, we built a web server named AbAgIntPre with two models corresponding to the generic and the SARS-CoV-specific models, respectively. AbAgIntPre takes the FASTA sequences of the antigen, the antibody heavy chain and the antibody light chain as its input. The user can select the corresponding prediction model according to the antigen type. We also provide three levels of stringent thresholds, corresponding to the false positive rates of 1%, 5%, and 10%. The prediction result can be displayed directly on the web page, while is also supported to be sent <italic>via</italic> the provided E-mail address. We hope that the introduction of AbAgIntPre can reduce unnecessary experimental procedures and provide hypotheses and supplements for accelerating the development of antibody drugs.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>Discussion</title>
    <p>The identification of antibody-antigen interaction is an essential problem in immunology and a prerequisite of antibody design and vaccine development. Although the experimental methods achieved the highest accuracy, these methods often need high cost of time, labor, and specific experimental conditions. Molecular docking based on protein structures is a common computational method for predicting antibody-antigen interactions (<xref rid="B22" ref-type="bibr">22</xref>). However, due to the difficulty in obtaining accurate structures of both antibody and antigen from sequences, predicting the interactions remains a difficult task. Mutual recognition of epitope and paratope is the key to specific binding of antigen and antibody. Many efforts have been devoted to predict the potential epitopes and paratopes based on ML methods (<xref rid="B23" ref-type="bibr">23</xref>–<xref rid="B25" ref-type="bibr">25</xref>), which provided insights into the characterization of antibodies and antigens through sequence features. Early studies have shown that the sequence components can well reflected the properties of antibodies and the amino acid preference of the epitopes (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). In this study, we used CKSAAP encoding as the preferred and compared it with several popular sequence encoding strategies. The independent test results showed that CKSAAP encoding based on the sequence composition is superior to any other encoding strategies.</p>
    <p>Although ML-based methods have been able to successfully predict potential paratopes and epitopes, direct prediction of antibody-antigen interaction remains a problem even if the epitopes or paratopes are known. The prediction of antibody-antigen interaction problem can be regard as a binary classification task. For well-known immunotherapy targets PD-1 and CTLA-4, the researchers have developed CNN model to predict interaction between antibodies and these two targets (<xref rid="B26" ref-type="bibr">26</xref>). Multi-head attention network was used to predict the binding of antibodies to SARS-CoV-2 S protein and influenza HA (<xref rid="B27" ref-type="bibr">27</xref>). Although these models performed well, they may not be able to predict unseen antigens due to their highly specific antigen scopes. For this reason, we established two prediction models, namely the generic prediction model and SARS-CoV-specific prediction model by using CNN architecture with CKSAAP sequence encoding strategy. Compared with the traditional ML methods, our results showed that the CNN architecture performs better both in the generic prediction model and SARS-CoV-specific prediction model. For the convenience of the community, we built the AbAgIntPre web server. Users can input the sequences of antigens and antibodies respectively to obtain the prediction results.</p>
    <p>Although the performance of our prediction models is competitive, the applicable domain of our models is still limited. The generic prediction model achieves the purpose of prediction by learning the binding patterns of different types of antigens and antibodies, but it cannot accurately discern antibody-antigen pairs with subtle sequence variations. Therefore, the generic model is suitable for primary antibody-antigen pair screening, but not for precise antibody design. On the other hand, the SARS-CoV-specific model can more precisely predict whether an antibody-antigen pair can interact when the antibody or antigen sequences are similar to each other, but it is only applicable to SARS-CoV antibody-antigen pairs. Apparently, the quantity and diversity of antigens and antibodies in the training set directly affects the performance of our model in practical application. SAbDab contained all the antibody structures available in the PDB and we used these data to train the generic model (<xref rid="B20" ref-type="bibr">20</xref>). But the antibody/antigen coverage of SAbDab is still not fully satisfactory, and more exhaustive antibody-antigen interaction data with sequence annotations are required to improve the prediction. In addition to SAbDAb, we have also searched other popular immune-related databases (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B16" ref-type="bibr">16</xref>–<xref rid="B19" ref-type="bibr">19</xref>) for available training data. IMGT and Abysis are two well-known databases that provide a wealth of antibody data as well as a series of search tools. However, they mainly provide the germline sequences of antibodies and have no corresponding antigen information. IEDB houses abundant manually curated epitope data and most antibody-specific epitopes have been already included in the SAbDAb database. iReceptor and Observed Antibody Space collected NGS sequence data on B-cell receptors but there is no exact antigen information available. In summary, due to the limited data included in the public databases, there is still a prominent gap between the coverage of our training data and the real world. We believe that our models will perform better when more comprehensive and sizable antibody-antigen interaction data become available.</p>
  </sec>
  <sec sec-type="data-availability" id="s5">
    <title>Data availability statement</title>
    <p>Publicly available datasets were analyzed in this study. This data can be found here: The original data are available at public database SAbDab (<uri xlink:href="http://opig.stats.ox.ac.uk/webapps/newsabdab/sabdab/">http://opig.stats.ox.ac.uk/webapps/newsabdab/sabdab/</uri>) and CoV-AbDab (<uri xlink:href="http://opig.stats.ox.ac.uk/webapps/covabdab/">http://opig.stats.ox.ac.uk/webapps/covabdab/</uri>). The processed datasets and source code of AbAgIntPre are available at: <uri xlink:href="https://github.com/emersON106/AbAgIntPre">https://github.com/emersON106/AbAgIntPre</uri>. The web server of AbAgIntPre is available at <uri xlink:href="http://www.zzdlab.com/AbAgIntPre">http://www.zzdlab.com/AbAgIntPre</uri>.</p>
  </sec>
  <sec sec-type="author-contributions" id="s6">
    <title>Author contributions</title>
    <p>YZ and ZZ designed and supervised the study. YH performed the analysis, built the model and webserver, and drafted the manuscript. YZ and ZZ revised the manuscript. All authors contributed to the article and approved the submitted version.</p>
  </sec>
</body>
<back>
  <sec sec-type="funding-information" id="s7">
    <title>Funding</title>
    <p>This study was supported by National Key Research and Development Program of China (2021YFF1201201 to YZ) and National Natural Science Foundation of China (32270703 to ZZ).</p>
  </sec>
  <ack>
    <title>Acknowledgments</title>
    <p>We greatly appreciate the researchers who developed the databases used in our study.</p>
  </ack>
  <sec sec-type="COI-statement" id="s8">
    <title>Conflict of interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
  <sec sec-type="disclaimer" id="s9">
    <title>Publisher’s note</title>
    <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <label>1</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonegawa</surname><given-names>S</given-names></name></person-group>. <article-title>Somatic generation of antibody diversity</article-title>. <source>Nature</source> (<year>1983</year>) <volume>302</volume>(<issue>5909</issue>):<page-range>575–81</page-range>. doi: <pub-id pub-id-type="doi">10.1038/302575a0</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansel</surname><given-names>TT</given-names></name><name><surname>Kropshofer</surname><given-names>H</given-names></name><name><surname>Singer</surname><given-names>T</given-names></name><name><surname>Mitchell</surname><given-names>JA</given-names></name><name><surname>George</surname><given-names>AJ</given-names></name></person-group>. <article-title>The safety and side effects of monoclonal antibodies</article-title>. <source>Nat Rev Drug Discovery</source> (<year>2010</year>) <volume>9</volume>(<issue>4</issue>):<page-range>325–38</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrd3003</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ecker</surname><given-names>DM</given-names></name><name><surname>Jones</surname><given-names>SD</given-names></name><name><surname>Levine</surname><given-names>HL</given-names></name></person-group>. <article-title>The therapeutic monoclonal antibody market</article-title>. <source>MAbs</source> (<year>2015</year>) <volume>7</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.4161/19420862.2015.989042</pub-id>
<pub-id pub-id-type="pmid">25529996</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichert</surname><given-names>JM</given-names></name></person-group>. <article-title>Antibodies to watch in 2017</article-title>. <source>MAbs</source> (<year>2017</year>) <volume>9</volume>(<issue>2</issue>):<page-range>167–81</page-range>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2016.1269580</pub-id>
</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mould</surname><given-names>DR</given-names></name><name><surname>Meibohm</surname><given-names>B</given-names></name></person-group>. <article-title>Drug development of therapeutic monoclonal antibodies</article-title>. <source>BioDrugs</source> (<year>2016</year>) <volume>30</volume>(<issue>4</issue>):<page-range>275–93</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s40259-016-0181-6</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name></person-group>. <article-title>A systematic review of sars-Cov-2 vaccine candidates</article-title>. <source>Signal Transduct Target Ther</source> (<year>2020</year>) <volume>5</volume>(<issue>1</issue>):<fpage>237</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-020-00352-y</pub-id>
<pub-id pub-id-type="pmid">33051445</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castells</surname><given-names>MC</given-names></name><name><surname>Phillips</surname><given-names>EJ</given-names></name></person-group>. <article-title>Maintaining safety with sars-Cov-2 vaccines</article-title>. <source>N Engl J Med</source> (<year>2021</year>) <volume>384</volume>(<issue>7</issue>):<page-range>643–9</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMra2035343</pub-id>
</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brussow</surname><given-names>H</given-names></name></person-group>. <article-title>Covid-19: Vaccination problems</article-title>. <source>Environ Microbiol</source> (<year>2021</year>) <volume>23</volume>(<issue>6</issue>):<page-range>2878–90</page-range>. doi: <pub-id pub-id-type="doi">10.1111/1462-2920.15549</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takashita</surname><given-names>E</given-names></name><name><surname>Kinoshita</surname><given-names>N</given-names></name><name><surname>Yamayoshi</surname><given-names>S</given-names></name><name><surname>Sakai-Tagawa</surname><given-names>Y</given-names></name><name><surname>Fujisaki</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Efficacy of antibodies and antiviral drugs against covid-19 omicron variant</article-title>. <source>N Engl J Med</source> (<year>2022</year>) <volume>386</volume>(<issue>10</issue>):<page-range>995–8</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMc2119407</pub-id>
</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westendorf</surname><given-names>K</given-names></name><name><surname>Zentelis</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Foster</surname><given-names>D</given-names></name><name><surname>Vaillancourt</surname><given-names>P</given-names></name><name><surname>Wiggin</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Ly-Cov1404 (Bebtelovimab) potently neutralizes sars-Cov-2 variants</article-title>. <source>Cell Rep</source> (<year>2022</year>) <volume>39</volume>(<issue>7</issue>):<elocation-id>110812</elocation-id>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2022.110812</pub-id>
<pub-id pub-id-type="pmid">35568025</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cavazzoni</surname><given-names>P</given-names></name></person-group>. <source>Coronavirus (Covid-19) update: Fda limits use of certain monoclonal antibodies to treat covid-19 due to the omicron variant</source>. <publisher-name>US Food and Drug Administration</publisher-name> (<year>2022</year>). Available at: <uri xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron</uri> [Accessed <date-in-citation content-type="access-date">September 26, 2022</date-in-citation>].</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Velgos</surname><given-names>SN</given-names></name><name><surname>Boddapati</surname><given-names>SP</given-names></name><name><surname>Sierks</surname><given-names>MR</given-names></name></person-group>. <article-title>Probing antibody-antigen interactions</article-title>. <source>Microbiol Spectr</source> (<year>2014</year>) <volume>2</volume>(<issue>1</issue>):<fpage>AID</fpage>–<lpage>0010-2013</lpage>. doi: <pub-id pub-id-type="doi">10.1128/microbiolspec.AID-0010-2013</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grange</surname><given-names>RD</given-names></name><name><surname>Thompson</surname><given-names>JP</given-names></name><name><surname>Lambert</surname><given-names>DG</given-names></name></person-group>. <article-title>Radioimmunoassay, enzyme and non-Enzyme-Based immunoassays</article-title>. <source>Br J Anaesth</source> (<year>2014</year>) <volume>112</volume>(<issue>2</issue>):<page-range>213–6</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bja/aet293</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefranc</surname><given-names>MP</given-names></name></person-group>. <article-title>Imgt, the international immunogenetics information system</article-title>. <source>Cold Spring Harb Protoc</source> (<year>2011</year>) <volume>2011</volume>(<issue>6</issue>):<fpage>595</fpage>–<lpage>603</lpage>. doi: <pub-id pub-id-type="doi">10.1101/pdb.top115</pub-id>
<pub-id pub-id-type="pmid">21632786</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chailyan</surname><given-names>A</given-names></name><name><surname>Tramontano</surname><given-names>A</given-names></name><name><surname>Marcatili</surname><given-names>P</given-names></name></person-group>. <article-title>A database of immunoglobulins with integrated tools: Digit</article-title>. <source>Nucleic Acids Res</source> (<year>2012</year>) <volume>40</volume>(<issue>Database issue</issue>):<page-range>D1230–4</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkr806</pub-id>
</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swindells</surname><given-names>MB</given-names></name><name><surname>Porter</surname><given-names>CT</given-names></name><name><surname>Couch</surname><given-names>M</given-names></name><name><surname>Hurst</surname><given-names>J</given-names></name><name><surname>Abhinandan</surname><given-names>KR</given-names></name><name><surname>Nielsen</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Abysis: Integrated antibody sequence and structure-management, analysis, and prediction</article-title>. <source>J Mol Biol</source> (<year>2017</year>) <volume>429</volume>(<issue>3</issue>):<page-range>356–64</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jmb.2016.08.019</pub-id>
</mixed-citation>
    </ref>
    <ref id="B17">
      <label>17</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrie</surname><given-names>BD</given-names></name><name><surname>Marthandan</surname><given-names>N</given-names></name><name><surname>Zimonja</surname><given-names>B</given-names></name><name><surname>Jaglale</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Barr</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Ireceptor: A platform for querying and analyzing Antibody/B-cell and T-cell receptor repertoire data across federated repositories</article-title>. <source>Immunol Rev</source> (<year>2018</year>) <volume>284</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1111/imr.12666</pub-id>
<pub-id pub-id-type="pmid">29944754</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovaltsuk</surname><given-names>A</given-names></name><name><surname>Leem</surname><given-names>J</given-names></name><name><surname>Kelm</surname><given-names>S</given-names></name><name><surname>Snowden</surname><given-names>J</given-names></name><name><surname>Deane</surname><given-names>CM</given-names></name><name><surname>Krawczyk</surname><given-names>K</given-names></name></person-group>. <article-title>Observed antibody space: A resource for data mining next-generation sequencing of antibody repertoires</article-title>. <source>J Immunol</source> (<year>2018</year>) <volume>201</volume>(<issue>8</issue>):<page-range>2502–9</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1800708</pub-id>
</mixed-citation>
    </ref>
    <ref id="B19">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vita</surname><given-names>R</given-names></name><name><surname>Mahajan</surname><given-names>S</given-names></name><name><surname>Overton</surname><given-names>JA</given-names></name><name><surname>Dhanda</surname><given-names>SK</given-names></name><name><surname>Martini</surname><given-names>S</given-names></name><name><surname>Cantrell</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>The immune epitope database (Iedb): 2018 update</article-title>. <source>Nucleic Acids Res</source> (<year>2019</year>) <volume>47</volume>(<issue>D1</issue>):<page-range>D339–D43</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gky1006</pub-id>
</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunbar</surname><given-names>J</given-names></name><name><surname>Krawczyk</surname><given-names>K</given-names></name><name><surname>Leem</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>T</given-names></name><name><surname>Fuchs</surname><given-names>A</given-names></name><name><surname>Georges</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Sabdab: The structural antibody database</article-title>. <source>Nucleic Acids Res</source> (<year>2014</year>) <volume>42</volume>(<issue>Database issue</issue>):<page-range>D1140–6</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkt1043</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raybould</surname><given-names>MIJ</given-names></name><name><surname>Kovaltsuk</surname><given-names>A</given-names></name><name><surname>Marks</surname><given-names>C</given-names></name><name><surname>Deane</surname><given-names>CM</given-names></name></person-group>. <article-title>Cov-abdab: The coronavirus antibody database</article-title>. <source>Bioinformatics</source> (<year>2021</year>) <volume>37</volume>(<issue>5</issue>):<page-range>734–5</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btaa739</pub-id>
</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dauzhenka</surname><given-names>T</given-names></name><name><surname>Kundrotas</surname><given-names>PJ</given-names></name><name><surname>Vakser</surname><given-names>IA</given-names></name></person-group>. <article-title>Computational feasibility of an exhaustive search of side-chain conformations in protein-protein docking</article-title>. <source>J Comput Chem</source> (<year>2018</year>) <volume>39</volume>(<issue>24</issue>):<page-range>2012–21</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jcc.25381</pub-id>
</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittala</surname><given-names>S</given-names></name><name><surname>Bailey-Kellogg</surname><given-names>C</given-names></name></person-group>. <article-title>Learning context-aware structural representations to predict antigen and antibody binding interfaces</article-title>. <source>Bioinformatics</source> (<year>2020</year>) <volume>36</volume>(<issue>13</issue>):<fpage>3996</fpage>–<lpage>4003</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btaa263</pub-id>
<pub-id pub-id-type="pmid">32321157</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jespersen</surname><given-names>MC</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name><name><surname>Marcatili</surname><given-names>P</given-names></name></person-group>. <article-title>Bepipred-2.0: Improving sequence-based b-cell epitope prediction using conformational epitopes</article-title>. <source>Nucleic Acids Res</source> (<year>2017</year>) <volume>45</volume>(<issue>W1</issue>):<page-range>W24–W9</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkx346</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krawczyk</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Baker</surname><given-names>T</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Deane</surname><given-names>CM</given-names></name></person-group>. <article-title>Improving b-cell epitope prediction and its application to global antibody-antigen docking</article-title>. <source>Bioinformatics</source> (<year>2014</year>) <volume>30</volume>(<issue>16</issue>):<page-range>2288–94</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btu190</pub-id>
</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>YW</given-names></name><name><surname>Adler</surname><given-names>AS</given-names></name><name><surname>Johnson</surname><given-names>DS</given-names></name></person-group>. <article-title>Predicting antibody binders and generating synthetic antibodies using deep learning</article-title>. <source>MAbs</source> (<year>2022</year>) <volume>14</volume>(<issue>1</issue>):<elocation-id>2069075</elocation-id>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2022.2069075</pub-id>
<pub-id pub-id-type="pmid">35482911</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Wu</surname><given-names>NC</given-names></name></person-group>. <article-title>A Large-scale systematic survey reveals recurring molecular features of public antibody responses to sars-Cov-2</article-title>. <source>Immunity</source> (<year>2022</year>) <volume>55</volume>(<issue>6</issue>):<fpage>1105</fpage>–<lpage>17 e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2022.03.019</pub-id>
<pub-id pub-id-type="pmid">35397794</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>M</given-names></name></person-group>. <article-title>Using support vector machine combined with auto covariance to predict protein-protein interactions from protein sequences</article-title>. <source>Nucleic Acids Res</source> (<year>2008</year>) <volume>36</volume>(<issue>9</issue>):<page-range>3025–30</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkn159</pub-id>
</mixed-citation>
    </ref>
    <ref id="B29">
      <label>29</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Niu</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group>. <article-title>Cd-hit: Accelerated for clustering the next-generation sequencing data</article-title>. <source>Bioinformatics</source> (<year>2012</year>) <volume>28</volume>(<issue>23</issue>):<page-range>3150–2</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/bts565</pub-id>
</mixed-citation>
    </ref>
    <ref id="B30">
      <label>30</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>JD</given-names></name><name><surname>Higgins</surname><given-names>DG</given-names></name><name><surname>Gibson</surname><given-names>TJ</given-names></name></person-group>. <article-title>Clustal W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice</article-title>. <source>Nucleic Acids Res</source> (<year>1994</year>) <volume>22</volume>(<issue>22</issue>):<page-range>4673–80</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/22.22.4673</pub-id>
</mixed-citation>
    </ref>
    <ref id="B31">
      <label>31</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebditch</surname><given-names>M</given-names></name><name><surname>Carballo-Amador</surname><given-names>MA</given-names></name><name><surname>Charonis</surname><given-names>S</given-names></name><name><surname>Curtis</surname><given-names>R</given-names></name><name><surname>Warwicker</surname><given-names>J</given-names></name></person-group>. <article-title>Protein-sol: A web tool for predicting protein solubility from sequence</article-title>. <source>Bioinformatics</source> (<year>2017</year>) <volume>33</volume>(<issue>19</issue>):<page-range>3098–100</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btx345</pub-id>
</mixed-citation>
    </ref>
    <ref id="B32">
      <label>32</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liaw</surname><given-names>C</given-names></name><name><surname>Tung</surname><given-names>CW</given-names></name><name><surname>Ho</surname><given-names>SY</given-names></name></person-group>. <article-title>Prediction and analysis of antibody amyloidogenesis from sequences</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>(<issue>1</issue>):<elocation-id>e53235</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0053235</pub-id>
<pub-id pub-id-type="pmid">23308169</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>HP</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Jian</surname><given-names>JW</given-names></name><name><surname>Yang</surname><given-names>AS</given-names></name></person-group>. <article-title>Origins of specificity and affinity in antibody-protein interactions</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2014</year>) <volume>111</volume>(<issue>26</issue>):<page-range>E2656–65</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1401131111</pub-id>
</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunik</surname><given-names>V</given-names></name><name><surname>Ofran</surname><given-names>Y</given-names></name></person-group>. <article-title>The indistinguishability of epitopes from protein surface is explained by the distinct binding preferences of each of the six antigen-binding loops</article-title>. <source>Protein Eng Des Sel</source> (<year>2013</year>) <volume>26</volume>(<issue>10</issue>):<fpage>599</fpage>–<lpage>609</lpage>. doi: <pub-id pub-id-type="doi">10.1093/protein/gzt027</pub-id>
<pub-id pub-id-type="pmid">23754530</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kringelum</surname><given-names>JV</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name><name><surname>Padkjaer</surname><given-names>SB</given-names></name><name><surname>Lund</surname><given-names>O</given-names></name></person-group>. <article-title>Structural analysis of b-cell epitopes in Antibody:Protein complexes</article-title>. <source>Mol Immunol</source> (<year>2013</year>) <volume>53</volume>(<issue>1-2</issue>):<fpage>24</fpage>–<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molimm.2012.06.001</pub-id>
<pub-id pub-id-type="pmid">22784991</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadam</surname><given-names>K</given-names></name><name><surname>Peerzada</surname><given-names>N</given-names></name><name><surname>Karbhal</surname><given-names>R</given-names></name><name><surname>Sawant</surname><given-names>S</given-names></name><name><surname>Valadi</surname><given-names>J</given-names></name><name><surname>Kulkarni-Kale</surname><given-names>U</given-names></name></person-group>. <article-title>Antibody Class(Es) predictor for epitopes (Abcpe): A multi-label classification algorithm</article-title>. <source>Front Bioinform</source> (<year>2021</year>) <volume>1</volume>:<elocation-id>709951</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fbinf.2021.709951</pub-id>
<pub-id pub-id-type="pmid">36303781</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Manzalawy</surname><given-names>Y</given-names></name><name><surname>Dobbs</surname><given-names>D</given-names></name><name><surname>Honavar</surname><given-names>V</given-names></name></person-group>. <article-title>Predicting flexible length linear b-cell epitopes</article-title>. <source>Comput Syst Bioinf Conf</source> (<year>2008</year>) <volume>7</volume>:<page-range>121–32</page-range>. doi: <pub-id pub-id-type="doi">10.1142/9781848162648_0011</pub-id>
</mixed-citation>
    </ref>
    <ref id="B38">
      <label>38</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group>. <article-title>Hcksaap_Ubsite: Improved prediction of human ubiquitination sites by exploiting amino acid pattern and properties</article-title>. <source>Biochim Biophys Acta</source> (<year>2013</year>) <volume>1834</volume>(<issue>8</issue>):<page-range>1461–7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.bbapap.2013.04.006</pub-id>
</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YZ</given-names></name><name><surname>Tang</surname><given-names>YR</given-names></name><name><surname>Sheng</surname><given-names>ZY</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group>. <article-title>Prediction of mucin-type O-glycosylation sites in mammalian proteins using the composition of K-spaced amino acid pairs</article-title>. <source>BMC Bioinf</source> (<year>2008</year>) <volume>9</volume>:<elocation-id>101</elocation-id>. doi: <pub-id pub-id-type="doi">10.1186/1471-2105-9-101</pub-id>
</mixed-citation>
    </ref>
    <ref id="B40">
      <label>40</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Paliwal</surname><given-names>K</given-names></name><name><surname>Litfin</surname><given-names>T</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group>. <article-title>Reaching alignment-Profile-Based accuracy in predicting protein secondary and tertiary structural properties without alignment</article-title>. <source>Sci Rep</source> (<year>2022</year>) <volume>12</volume>(<issue>1</issue>):<fpage>7607</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-022-11684-w</pub-id>
<pub-id pub-id-type="pmid">35534620</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>NQK</given-names></name><name><surname>Huynh</surname><given-names>TT</given-names></name><name><surname>Yapp</surname><given-names>EKY</given-names></name><name><surname>Yeh</surname><given-names>HY</given-names></name></person-group>. <article-title>Identification of clathrin proteins by incorporating hyperparameter optimization in deep learning and pssm profiles</article-title>. <source>Comput Methods Programs BioMed</source> (<year>2019</year>) <volume>177</volume>:<page-range>81–8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cmpb.2019.05.016</pub-id>
</mixed-citation>
    </ref>
    <ref id="B42">
      <label>42</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>CC</given-names></name><name><surname>Yan</surname><given-names>K</given-names></name></person-group>. <article-title>Deepsvm-fold: Protein fold recognition by combining support vector machines and pairwise sequence similarity scores generated by deep learning networks</article-title>. <source>Brief Bioinform</source> (<year>2020</year>) <volume>21</volume>(<issue>5</issue>):<page-range>1733–41</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bib/bbz098</pub-id>
</mixed-citation>
    </ref>
    <ref id="B43">
      <label>43</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altschul</surname><given-names>SF</given-names></name><name><surname>Madden</surname><given-names>TL</given-names></name><name><surname>Schaffer</surname><given-names>AA</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Miller</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Gapped blast and psi-blast: A new generation of protein database search programs</article-title>. <source>Nucleic Acids Res</source> (<year>1997</year>) <volume>25</volume>(<issue>17</issue>):<page-range>3389–402</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/25.17.3389</pub-id>
</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhasin</surname><given-names>M</given-names></name><name><surname>Raghava</surname><given-names>GP</given-names></name></person-group>. <article-title>Classification of nuclear receptors based on amino acid composition and dipeptide composition</article-title>. <source>J Biol Chem</source> (<year>2004</year>) <volume>279</volume>(<issue>22</issue>):<page-range>23262–6</page-range>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M401932200</pub-id>
</mixed-citation>
    </ref>
    <ref id="B45">
      <label>45</label>
      <mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name></person-group>. (<year>2015</year>). <article-title>Using Word2vec to Process Big Text Data</article-title>, in: <conf-name>Proceedings 2015 IEEE International Conference on Big Data (Big Data)</conf-name>. <publisher-loc>Santa Clara, CA, USA</publisher-loc>: <publisher-name>IEEE</publisher-name>. pp. <page-range>2895–7</page-range>.</mixed-citation>
    </ref>
    <ref id="B46">
      <label>46</label>
      <mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Lilleberg</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name></person-group>. (<year>2015</year>). <article-title>Support vector machines and Word2vec for text classification with semantic features</article-title>, in: <conf-name>Proceedings of 2015 IEEE 14th International Conference on Cognitive Informatics &amp; Cognitive Computing (Icci*Cc)</conf-name>. <publisher-loc>Beijing, China</publisher-loc>: <publisher-name>IEEE</publisher-name>. pp. <page-range>136–40</page-range>.</mixed-citation>
    </ref>
    <ref id="B47">
      <label>47</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sledzieski</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Cowen</surname><given-names>L</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name></person-group>. <article-title>D-script translates genome to phenome with sequence-based, structure-aware, genome-scale predictions of protein-protein interactions</article-title>. <source>Cell Syst</source> (<year>2021</year>) <volume>12</volume>(<issue>10</issue>):<fpage>969</fpage>–<lpage>82 e6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cels.2021.08.010</pub-id>
<pub-id pub-id-type="pmid">34536380</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Ju</surname><given-names>CJ</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>KW</given-names></name><etal/></person-group>. <article-title>Multifaceted protein-protein interaction prediction based on Siamese residual rcnn</article-title>. <source>Bioinformatics</source> (<year>2019</year>) <volume>35</volume>(<issue>14</issue>):<page-range>i305–i14</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btz328</pub-id>
</mixed-citation>
    </ref>
    <ref id="B49">
      <label>49</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Wuchty</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group>. <article-title>Transfer learning <italic>Via</italic> multi-scale convolutional neural layers for human-virus protein-protein interaction prediction</article-title>. <source>Bioinformatics</source> (<year>2021</year>) <volume>37</volume>(<issue>24</issue>):<page-range>4771–8</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btab533</pub-id>
</mixed-citation>
    </ref>
    <ref id="B50">
      <label>50</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>WT</given-names></name><name><surname>Musharrafieh</surname><given-names>R</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Dueker</surname><given-names>K</given-names></name><name><surname>Tse</surname><given-names>LV</given-names></name><name><surname>Martinez</surname><given-names>DR</given-names></name><etal/></person-group>. <article-title>Targeted isolation of diverse human protective broadly neutralizing antibodies against sars-like viruses</article-title>. <source>Nat Immunol</source> (<year>2022</year>) <volume>23</volume>(<issue>6</issue>):<page-range>960–70</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41590-022-01222-1</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
